{
  "ticker": "LDX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970908",
  "id": "02970908",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250721",
  "time": "0858",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lz918nk56b57.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Investment Highlights (Key Takeaways)**  \n- **Major Distribution Agreement**: PHASE Scientific signed for U.S. distribution of FebriDx\u00ae\u2014potential **US$317M (A$487M)** over 6 years, contingent on CLIA waiver approval. Without waiver, contract capped at **US$25M**.  \n- **CLIA Waiver Progress**: 105/120 bacterial-positive patients enrolled; FDA submission expected within **3 months**.  \n- **Funding**:  \n  - **Loan Facility**: Binding term sheet for **A$5M** working capital loan (12-month term + extension option).  \n  - **Non-Dilutive Funding**: **US$15.6M** received in past 2 years; **US$7.1M** committed from BARDA.  \n- **Revenue**: FY25 revenue **US$12.4M** (+12% YoY); Q4 revenue **US$2.6M** (-26% QoQ due to seasonal flu decline).  \n- **Cash Balance**: **US$2.0M** as of 30 June 2025.  \n\n#### **Operational Updates**  \n- **Hologic fFN Project**: Phase 2 completed; **3-month delay** for additional assay studies.  \n- **Medicare Coverage**: 85% U.S. Medicare reimbursement secured for FebriDx\u00ae.  \n\n#### **Catalysts**  \n- CLIA waiver submission (within 3 months).  \n- Pediatric study launch (BARDA-funded).  \n- PHASE Scientific partnership execution.  \n\n**Omitted**: Background details, disclaimers, non-material project timelines.",
  "usage": {
    "prompt_tokens": 6421,
    "completion_tokens": 347,
    "total_tokens": 6768,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T23:10:15.589273"
}